InsidersTradesSigma
Browse the detailed record of transactions filed by Melnick David A., Directeur Médical. Director active across 1 companies, notably Spero Therapeutics, Inc.. Aggregated, 4 disclosures have been recorded. The latest transaction was disclosed on 1 February 2022 (Attribution). Regulator: SEC (Form 4). All data is free.
4 of 4 declarations
David A. Melnick serves as Chief Medical Officer at Spero Therapeutics, Inc. In this role, he is responsible for leading the company's medical initiatives and clinical research. With a strong background in the pharmaceutical sector, David contributes to innovation and treatment improvement. His leadership is essential in ensuring that Spero Therapeutics adheres to ethical and scientific standards.